2-Cyclohexylcarbonylbenzimidazoles as potent, orally available and brain-penetrable opioid receptor-like 1 (ORL1) antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 11, 2009, Pages 3096-3099

  Kobayashi, Kensuke ^a   Uchiyama, Minaho ^a   Takahashi, Hirobumi ^a   Kawamoto, Hiroshi ^a   Ito, Satoru ^a   Yoshizumi, Takashi ^a   Nakashima, Hiroshi ^a   Kato, Tetsuya ^a   Shimizu, Atsushi ^a   Yamamoto, Izumi ^a   Asai, Masanori ^a   Miyazoe, Hiroshi ^a   Ohno, Akio ^a   Hirayama, Mioko ^a   Ozaki, Satoshi ^a   Tani, Takeshi ^a   Ishii, Yasuyuki ^a   Tanaka, Takeshi ^a   Mochidome, Takanobu ^a   Tadano, Kiyoshi ^a   Fukuroda, Takahiro ^a   Ohta, Hisashi ^a   Okamoto, Osamu ^a   more..

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Benzimidazole; Nociceptin orphanin FQ; ORL1 antagonist; P glycoprotein (P gp)

Indexed keywords

2 CYCLOHEXYLCARBONYLBENZIMIDAZOLE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; GLYCOPROTEIN P; ION CHANNEL; OPIATE ANTAGONIST; SULFIDE; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; BRAIN; CALCIUM ANTAGONISM; DRUG PENETRATION; EXPERIMENTAL ANIMAL; HUMAN; NONHUMAN; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; BENZIMIDAZOLES; BRAIN; CELL LINE; CYCLOHEXANES; DOGS; HAPLORHINI; HUMANS; HYPERALGESIA; P-GLYCOPROTEIN; RATS; RECEPTORS, OPIOID;

ANIMALIA;

EID: 65149101695     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.023     Document Type: Article

References (27)

1. It is reported prior to this communication as a consecutive series. Kobayashi K., Kato T., Yamamoto I., Shimizu A., Mizutani S., Asai M., Kawamoto H., Ito S., Yoshizumi T., Hirayama M., Ozaki S., Ohta H., and Okamoto O. Bioorg. Med. Chem. Lett. 19 (2009) 3100
2. Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., Caput D., Vassart G., and Meunier J.C. FEBS Lett. 341 (1994) 33
3. Fukuda K., Kato S., Mori K., Nishi M., Takeshima H., Iwabe N., Miyata T., Houtani T., and Sugimoto T. FEBS Lett. 343 (1994) 42
4. Chen Y., Fan Y., Liu J., Mestek A., Tian M.T., Kozak C.A., and Yu L. FEBS Lett. 347 (1994) 279
5. Pan Y.X., Cheng J., Xu J., Rossi G., Jacobson E., Ryanmoro J., Brooks A.I., Dean G.E., Standifer K.M., and Pasternak G.W. Mol. Pharmacol. 47 (1995) 1180
6. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma F.J., and Civelli O. Science 270 (1995) 792
7. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., Mazarguil H., Vassart G., Parmentier M., and Costentin J. Nature 377 (1995) 532
8. Mogil J.S., Grisel J.E., Reinscheid K.K., Civelli O., Belknap J.K., and Grandy D.K. Neuroscience 75 (1996) 333
9. Ueda H., Yamaguchi T., Tokuyama S., Inoue M., Nishi M., and Takeshima H. Neurosci. Lett. 237 (1997) 136
10. Yu T.P., Fein J., Phan T., Evans C.J., and Xie C.W. Hippocampus 7 (1997) 88
11. Sandin J., Georgieva J., Schott P.A., Ogren S.O., and Terenius L. Eur. J. Neurosci. 9 (1997) 194
12. Manabe T., Noda Y., Mamiya T., Katagiri H., Houtani T., Nishi M., Noda T., Takahashi T., Sugimoto T., Nabeshima T., and Takeshima H. Nature 394 (1998) 577
13. Pomonis J.D., Billington C.J., and Levine A.S. Neuroreport 8 (1996) 369
14. Jenck F., Moreau J.L., Martin J.R., Kilpatrick G.J., Reinscheid R.K., Monsma F.J., Nothacker H.P., and Civelli O. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 14854
15. Gumusel B., Hao Q.Z., Hyman A., Chang J.K., Kapusta D.R., and Lippton H. Life Sci. 60 (1997) L141
16. Champion H.C., and Kadowitz P.J. Life Sci. 60 (1997) L241
17. Florin S., Suaudeau C., Meunier J.C., and Costentin J. Eur. J. Pharmacol. 317 (1996) 9
18. Champion H.C., Wang R., Hellstrom W.J.G., and Kadowitz P.J. Am. J. Physiol. 36 (1997) E214
19. 35S]GTPγS binding method.
20. J-113,397 (Kawamoto, H.; Ozaki, S.; Itoh, Y.; Miyaji, M.; Arai, S.; Nakashima, H.; Kato, T.; Ohta, H.; Iwasawa, Y. J. Med. Chem. 1999, 42, 5061) was used as an internal control across all assay plates for data validation.
21. Hochman J.H., Yamazaki M., Ohe T., and Lin J.H. Curr. Drug Metab. 3 (2002) 257
22. Okamoto O., Kobayashi K., Kawamoto H., Ito S., Satoh A., Kato T., Yamamoto I., Mizutani S., Hashimoto M., Shimizu A., Sakoh H., Nagatomi Y., Iwasawa Y., Takahashi H., Ishii Y., Ozaki S., and Ohta H. Bioorg. Med. Chem. Lett. 18 (2008) 3278
23. Okamoto O., Kobayashi K., Kawamoto H., Ito S., Yoshizumi T., Yamamoto I., Hashimoto M., Shimizu A., Takahashi H., Ishii Y., Ozaki S., and Ohta H. Bioorg. Med. Chem. Lett. 18 (2008) 3282
24. Cox C.D., Coleman P.J., Breslin M.J., Whitman D.B., Garbaccio R.M., Fraley M.E., Buser C.A., Walsh E.S., Hamilton K., Schaber M.D., Lobell R.B., Tao W., Davide J.P., Diehl R.E., Abrams M.T., South V.J., Huber H.E., Torrent M., Prueksaritanont T., Li C., Slaughter D.E., Mahan E., Fernandez-Metzler C., Yan Y., Kuo L.C., Kohl N.E., and Hartman G.D. J. Med. Chem. 51 (2008) 4239
25. Human microsomal stability was determined by% parent compound (1 μM) remaining after 30 min (37 °C) incubation with human liver microsomes (0.25 mg protein/ml).
26. Jamieson C., Moir E.M., Rankovic Z., and Wishart G. J. Med. Chem. 49 (2006) 5029
27. +.